GT Biopharma is trading 5% up at $0.32, based on the provided live price; no clear catalyst has been identified.
- The latest significant disclosure located was the August 14, 2026 second-quarter report.
- The report cited approximately $5.1 million in cash and an expected operating runway through the fourth quarter.
- The broader market is moving lower, so macro sentiment does not clearly explain the gain.